Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Completed · Phase 1

Conditions studied: AML, ALL, Blast Crisis, MDS, Multiple Myeloma

In brief

This is a multicenter, open-label, dose escalation Phase 1 study.

Key facts

Study ID

NCT01204164

Run by

Tragara Pharmaceuticals, Inc.

People needed

120

Starts

2010-08-01

Expected to finish

2016-04-01

Last updated by the study team

2016-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• RMCC — Denver, Colorado, United States
• Emory — Atlanta, Georgia, United States
• Rush — Chicago, Illinois, United States
• IU — Indianapolis, Indiana, United States
• HUMC — Hackensack, New Jersey, United States
• Cornell — New York, New York, United States
• OSU — Columbus, Ohio, United States
• SCRI — Nashville, Tennessee, United States
• MDACC — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.